BLOG/🇺🇸United States··daily

Significant Contract Modifications ($10M+) — March 31, 2026

Significant Contract Modifications ($10M+)

8 total filings analysed

Executive Summary

NASA dominates with $2.06B in long-term space contracts (67% of total value) to RTX/Raytheon, Lockheed Martin, TRAX, and Caltech/JPL, signaling sustained U.S. space investment through 2029 and bullish revenue visibility for aerospace primes. Additional $1B+ across DoD, HHS, GSA supports defense, health security, and environmental sectors via multi-year awards to HII, Emergent BioSolutions, and Sevenson. Overall bullish (7/8 signals) with $3.06B total obligations, but monitor funding outlays (avg. 40% disbursed) and appropriations risks amid extended timelines.

Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from March 24, 2026.

Investment Signals(3)

  • NASA Space Contract Surge(HIGH)

    Four contracts totaling $2.06B to RTX/Raytheon ($1.22B), Lockheed ($301M), TRAX ($406M), and Caltech ($134M) provide 18+ year revenue streams in space vehicles/instruments.

  • Defense/Engineering Multi-Year Wins(HIGH)

    HII ($446M GSA engineering), Sevenson ($180M DoD remediation), and Hensel Phelps ($117M USGS construction) secure $743M in competed awards extending to 2032.

  • HHS Bio-Threat Revenue Lock-In(MEDIUM)

    Emergent BioSolutions' $256M botulism antitoxin contract through potential 2029 offers predictable pharma revenue amid preparedness focus.

Risk Flags(3)

  • Execution[HIGH RISK]

    Extended periods (avg. 10+ years to 2032) with low outlays (e.g., Raytheon $316M/1.22B, Lockheed $44M/301M) heighten funding cliffs and performance hurdles.

  • Regulatory[MEDIUM RISK]

    Cost-plus/award fee structures (7/8 contracts) tie payouts to audits/evaluations; foreign ownership in Emergent Canada adds sourcing scrutiny.

  • Market[MEDIUM RISK]

    Near-term expirations (TRAX July/Oct 2024) risk revenue gaps without renewals.

Opportunities(3)

  • $623M+ in unexercised options (e.g., HII $509M, Raytheon $32M) across contracts could unlock 20%+ upside if exercised.

  • NASA Goddard focus on space instruments/vehicles positions primes for follow-ons amid DSOC/MAVEN/VIRS programs.

  • Low/no competition awards (e.g., Raytheon, Emergent) indicate sticky revenue; small biz Sevenson win opens DoD remediation pipeline.

Sector Themes(3)

  • 67% of value ($2.06B) in NASA awards to Goddard/JPL for vehicles, instruments, logistics through 2029.

  • All contracts span 4-18+ years with cost-plus favoring incumbents amid full/open competition wins.

  • Beyond NASA: GSA/DoD/HHS/Interior spread $1B across engineering, remediation, bio-threats, construction.

Watch List(3)

  • 👁

    {"entity"=>"TRAX International", "reason"=>"Contract nears end (July/Oct 2024) with $118M remaining obligation post-$287M outlay.", "trigger"=>"Renewal or new NASA logistics RFP"}

  • 👁

    {"entity"=>"RTX/Raytheon NASA VIRS", "reason"=>"Largest at $1.22B with only 26% outlayed through 2029.", "trigger"=>"Option exercise for $32M upside or funding delays"}

  • 👁

    {"entity"=>"HII Mission Technologies", "reason"=>"$446M obligated/$955M potential via GSA; ends 2025.", "trigger"=>"Follow-on task orders post-2025"}

Get daily alerts with 3 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 8 filings

🇺🇸 More from United States

View all →